INTRODUCTION

Multiple primary cancers (MPC) or multiple primary malignant neoplasms (MPN) is defined as the occurrence of at least two malignant neoplasms in an individual regardless of the time and organ of detection with no metastatic origin. Metachronous multiple primary cancers occur in at least 6-month period of time. Herein, we present a case of a patient with metachronous neoplasms of the rectum, breast, and mediastinum.

CASE PRESENTATION

A 42-year-old female patient with intellectual disability was referred to our center for the resection of a mediastinal mass, diagnosed as thymoma. She was identified as a case of multiple primary cancers, including adenocarcinoma of the rectum, carcinoma of the breast, and mediastinal thymoma, in a 15-year period, who underwent chemotherapy, radiotherapy, and surgical resection.

KEYWORDS
breast neoplasms, metachronous neoplasms, multiple primary cancers, multiple primary neoplasms, second primary neoplasms, thymus neoplasms
centrally calcified anterior mediastinal mass, pointed to the left side, measuring in dimension about 78 × 52 mm at the level of the aortic arch. Fine needle aspiration of the left thyroid lobe reported benign follicular nodule (adenomatous goiter with focal lymphocytic thyroiditis), and the tru-cut biopsy of the mediastinal mass showed epithelial neoplasm with foci vagus glands formation.

A year later, she had taken another chest CT, which showed a mass containing calcification with a size of approximately 124 × 113 × 80 mm in the anterior mediastinum. The mass was extended to the thoracic inlet with heterogeneous enhancement after contrast injection. Another tru-cut biopsy was taken. According to the immunohistochemical study and morphology, the tumor was reported to be a thymoma type A. The immunohistochemical study result was positive for LCA (rarely positive), CK, EMA (weak scattered positive), CD5 (rare scattered positive), and HMWCK (rare scattered positive) and was negative for GATA3, PAX-8, CDX2, CK7, CK20, and desmin. Therefore, the patient was referred to our center for tumor resection.

Thyroid evaluation had been performed before operation, revealing nothing in favor of hypothyroidism or hyperthyroidism. So, performing the surgery was safe and unimpeded.

We performed a CT scan (Figure 1) and operated on the patient. After general anesthesia in the supine position, a complete sternotomy was done. Exploration showed a very large anterior mediastinal mass with an extension to the apex of the left chest cavity and inferior of the neck with an encasement of innominate vein and adhesion to great vessels of the aortic arch. The mediastinal mass was removed from the tissues and organs to which it was attached and was resected completely. Besides, due to the large nodule of the left lobe of the thyroid, thyroidectomy was done. Also, a thymectomy was performed. The operation ended successfully with bilateral mediastinal pleurectomy and bilateral chest tube insertion. The resected mass was sent for pathological evaluation.

Gross examination showed a large semi-ovoid gray well-defined rubbery mass measuring 12 × 10 × 7 cm attached to the thymus. Cut sections showed a homogenous creamy surface with foci of hemorrhage and ossification. Histopathologic examination revealed lobulated architecture with cellular lobules and intersecting fibrous bands (Figure 2A). Neoplastic epithelial cells were polygonal with moderate atypia and mitosis (Figure 2B). No necrosis was identified. There were rare lymphocytes. The capsular invasion was seen; however, no lymphovascular invasion was identified. Immunohistochemical study of
epithelial cells showed immunoreactivity for cytokeratin (Figure 3A) but no immunoreactivity for CD 5, CD117, p63, TTF-1, chromogranin, synaptophysin, CK 5/6, and monoclonal PAX-8. Rare lymphocytes were immunoreactive for CD 45 and CD 5 (Figure 3B). Ki-67 proliferation index was about 30% (Figure 3C). The diagnosis of thymoma (WHO) type B3 was confirmed according to the histopathological and immunohistochemical study.

3 | DISCUSSION

During the past decades, developments in the diagnosis and treatment of patients with cancer have improved life expectancy in cancer patients and introduced new findings in survivors of this disease. The incidence of subsequent primary cancer is higher in cancer survivors than in the normal population. The patient in our presentation fills the Warren and Gates criteria for second primary malignancy (SPM) and ICD-0 (third edition) for metachronous multiple malignancies as follows: (1) Histological confirmation of infiltrative well-differentiated adenocarcinoma of the rectum, invasive mucinous carcinoma of the breast, and thymoma type B3; all of which were separated by normal mucosa and not related to one another by histological origin, (2) the occurrence of three tumors was chronologically separated by at least 2 years. According to previous studies, breast cancer is one of the most common SPMs following colorectal cancer, which was seen in our case.

Souadjian et al. published one of the first papers on the relation between thymoma and occurrence of other primary cancers, in which the prevalence of other non-thymic malignant lesions was 21% in thymoma cases in contrast with 8% in parathyroid cancer cases, which was presented as the control group. Also, there are few cases in literature for MPCs, including thymoma; Šitić et al. presented an almost similar case of a patient with breast cancer, rectal adenocarcinoma, lung carcinoma, and thymoma; Tanimura et al. reported a series of 97 cases presented with thymoma, in 7 of which another malignant lesion in other organs was also presented (1 case of breast and 1 case of colon); Tehrani et al. reported 2 cases of MPCs including thymoma; Athanasiou et al. reported a case of MPCs, including thymoma and breast cancer; and Welsh et al. presented 136 cases of thymoma, in which in 38 cases, a second and even a third neoplasm also occurred (12 cases of colorectal carcinoma and 4 cases of breast carcinoma).
Causes of MPC have not been systematically studied; yet, Motuzyuk et al. suggest the following as probable causes: (1) Endogenous factors, such as abnormal embryonic development, immunity-related diseases, and endocrine diseases affecting sensitivity to carcinogens, (2) environmental and lifestyle exposures, including long-term effects of radiation and industrial pollution, (3) genetic determinants, such as BRCA 1/2 genes, and (4) iatrogenic effect, especially radiation therapy and drug therapy.13

Genetic predisposition plays an important role in presenting cancer in individuals,14 and there are known inherited cancer syndromes that are caused by single or multiple gene mutations.15,16 A case of thymoma was reported by Principe et al., which was accompanied by deleterious BRCA2 mutation, a gene mostly seen in breast cancer but proven unrelated to colorectal cancer.17 Also, another case of thymoma was reported by Tampellini et al., which was accompanied by Lynch syndrome.18 In another case series, three patients with a family history of upper aero-digestive tract squamous carcinoma developed MPC, suggesting an inherited predisposition.19 Kotnis et al reported in distinct ethnic groups, risk for different cancers could be modulated by interaction between different exogenous and endogenous carcinogens and genetic variants.20 Increasing biological and genetical understanding of MPC could assist in management planning and early diagnosis and preventing of carcinogenetic risk factors.

Intellectual disability, as the sole past medical condition of our patient, has been investigated as an associated condition with cancer in a cohort study by Liu et al., in which they showed that the prevalence of any type of cancer was higher in patients with intellectual disability that could not be explained by heritability. Additionally, they reported statistically significant associations for cancers of the digestive system and intellectual disability.21 Proposed mechanisms for this association include the role of multiple-system congenital anomalies22 and extrinsic factors, such as lack of fiber intake and low physical exercise.23

### 4 CONCLUSION

MPC is a rare condition in the literature, and only a few studies have reported and described it, but as the cancer survivor population continues to grow, the need for an evidence-based protocol for evaluation and screening for it also arises. We also recommend a similar strategy for patients with an intellectual disability, considering the poor emphasis on a healthy lifestyle and possible lack of expression of signs and symptoms related to other malignancies.
AUTHOR CONTRIBUTIONS
M.A. and N.S. made the histopathological diagnosis of the case, while P.M. carried out the therapeutic measures. M.F. and H.K. collected the data and drafted the manuscript. H.K. and R.S. revised and proofread the manuscript. All authors read and approved the final version of the manuscript.

ACKNOWLEDGMENT
None to declare.

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

DATA AVAILABILITY STATEMENT
All data regarding this case report has been reported in the manuscript. Please contact the corresponding author in case of requiring any further information.

ETHICS APPROVAL
The present study was approved by the Medical Ethics Committee of Shiraz University of Medical Sciences.

CONSENT
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

ORCID
Reza Shahriarirad https://orcid.org/0000-0001-5454-495X

REFERENCES
1. Working Group R. International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev. 2005;14(4):307-308.
2. Centers for Disease C. Prevention. Cancer survivorship–6.
3. Halamkova J, Kazda T, Pehalova L, et al. Second primary malignancies in colorectal cancer patients. Sci Rep. 2021;11(1):2759.
4. Utada M, Ohno Y, Hori M, Soda M. Incidence of multiple primary malignant neoplasms in colorectal cancer patients. Sci Rep. 2021;11(1):2759.
5. Warren S. Multiple primary malignant tumors. A survey of the literature and a statistical study. Am J Cancer. 1932;16:1358-1414.
6. Yamamoto S, Yoshimura K, Ri S, Fujita S, Akasu T, Moriya Y. The risk of multiple primary malignancies with colorectal carcinoma. Dis Colon Rectum. 2006;49(10 Suppl):S30-S36.
7. Souadjian JV, Silverstein MN, Titus JL. Thymoma and cancer. Cancer. 1968;22(6):1221-1225.
8. Štíč S, Mírt-Dabič M, Brčič L, Juroš Z, Hutínc Z, Krušlin B. DNA ploidy in thymoma and associated multiple primary malignancies in the same patient. Acta Clin Croat. 2008;47(3):155-159.

9. Tanimura S, Kouno T, Matsushita H. A study of thymoma associated with cancer of the other organs. Kyobu Geka. 2002;55(11):986-989.
10. Tehrani OS, Chen EQ, Schaebeler DL, Mughal AW. Thymoma associated with malignancies may herald a hereditary cancer syndrome. Fam Cancer. 2010;9(4):655-657.
11. Athanasiou E, Michalopoulou-Manoloutsiou E, Bobos M, et al. Coincidence of thymoma and breast cancer and in a 56-year-old female patient. Ann Trans Med. 2016;4(22):446.
12. Welsh JS, Wilkins KB, Green R, et al. Association between thymoma and second neoplasms. JAMA. 2000;283(9):1142-1143.
13. Motuzuky I, Sydorchuk O, Koutvn N, Palian Z, Kostiuchenko Y. Analysis of trends and factors in breast multiple primary malignant neoplasms. Breast Cancer (Auckl). 2018;12:117823418759959.
14. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23(2):276-292.
15. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science. 1997;278(5340):1043-1050.
16. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene. 2004;23(38):6445-6470.
17. Principe DR, Kamath SD, Munshi HG, Mohindra NA. Metastatic thymoma harboring a deleterious BRCA2 mutation derives durable clinical benefit from Olaparib. Oncologist. 2020;25(4):301-305.
18. Tampellini M, Alabiso I, Sculli CM, et al. Stage IB malignant thymoma in a lymph node syndrome patient with multiple cancers: response to incidental administration of oxaliplatin and 5-fluorouracil. J Chemother. 2006;18(4):433-436.
19. Jhavar S, Sarin R, Mulherkar R, Benner A, Prakash Agarwal J, Dinshaw K. Glutathione S-transferase M1 or T1 null genotype as a risk factor for developing multiple primary neoplasms in the upper aero-digestive tract, in Indian males using tobacco. Oral Oncol. 2004;40(1):84-91.
20. Kotnis A, Kannan S, Sarin R, Mulherkar R. Case–control study and meta-analysis of SULT1A1 Arg213His polymorphism for gene, ethnicity and environment interaction for cancer risk. Br J Cancer. 2008;99(8):1340-1347.
21. Liu Q, Adami HO, Reichenberg A, Kolvezon A, Fang F, Sandin S. Cancer risk in individuals with intellectual disability in Sweden: a population-based cohort study.PLoS Med. 2021;18(10):e1003840.
22. Sawardek KP. Profile of major congenital malformations at Nizwa hospital, Oman: 10-year review. J Paediatr Child Health. 2005;41(7):323-330.
23. Willis D, Samalin E, Satge D. Colorectal cancer in people with intellectual disabilities. Oncology. 2018;95(6):322-336.

How to cite this article: Mardani P, Fallahi M, Kamran H, Shahriarirad R, Anbardar MH, Soleimani N. Mediastinal thymoma in a patient with previous rectal and breast cancers: A report of a case with multiple primary cancers and review of literature. Clin Case Rep. 2022;10:e05987. doi: 10.1002/ccr3.5987